Background Hemorrhage remains the leading cause of preventable death after trauma. The XSTAT® expandable minisponge hemostatic device was developed for the control of severe, life-threatening bleeding from junctional wounds not amenable to tourniquet application. This is an initial report of the clinical use of this novel method of hemorrhage control for civilian penetrating injury. Methods A review of trauma admissions at a high volume level 1 trauma center was carried out from July 2016 to November 2017. All patients sustaining penetrating trauma with active hemorrhage were evaluated for XSTAT® use. Ten device deployments occurred during this time. Each deployment was reviewed in detail, capturing patient and injury data, efficacy of hemorrhage control, and evaluation of any potential device or treatment related complications. Results 6,363 trauma admissions were reviewed with 22.1% sustaining a penetrating mechanism of injury. XSTAT® was deployed in 10 (0.7%) penetrating trauma admissions with a mean age of 38.3 (range 16 – 59) years, SBP of 126.7 (range 74 – 194) mmHg, GCS 14.5 (range 13 – 15) and NISS of 9.5 (range 1 – 27). Eight patients had an identifiable arterial injury; the remainder had vein or soft tissue bleeding. Overall, half were junctional injuries. XSTAT® was able to stop bleeding in nine of ten patients on the first deployment, with the remaining patient requiring one repeat injection. Dwell times ranged from 1 to 40 hours (median = 15 h). There were no technical device failures or embolic complications. Retained sponges were identified in two patients on initial post removal x-rays following wound exploration for definitive hemorrhage control and sponge removal. No patient died during the study period. Conclusions XSTAT® use appears safe. It is rapid, reliable, and provides a high degree of hemorrhage control on first deployment. Sponge removal should always be followed by radiographic clearance. For patients with hemorrhage from cavitary wounds not amenable to tourniquet placement, this device was effective. Further study is warranted as XSTAT® use becomes more widespread. Level of Evidence V Study Type Case series Address for Correspondence and Reprints: Kenji Inaba, MD, FRCSC, FACS, Division of Trauma and Surgical Critical Care, LAC + USC Medical Center, University of Southern California, 2051 Marengo Street, Inpatient Tower, C5L100, Los Angeles, CA 90033, Phone: (323) 409-8597, Fax: (323) 441-9907. E-mail: kinaba@surgery.usc.edu Conflict of Interest The authors have no conflicts of interest or disclosures of funding to declare. © 2018 Lippincott Williams & Wilkins, Inc.
from Emergency Medicine via xlomafota13 on Inoreader https://ift.tt/2qdOTak
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Zusammenfassung Albträume werden von vielen Menschen zumindest gelegentlich erlebt. Allerdings ist auch die Albtraumstörung, bei der Albtr...
-
Abstract Background and aims The clinical course and responsiveness to antiviral treatments differs among hepatitis B virus (HBV) genoty...
-
Abstract Background Over 35 million alcohol impaired (AI) patients are cared for in Emergency Departments (EDs) annually. Emergency phys...
-
It’s up for debate whether the “best EMS movie” has actually been made yet. The Hollywood take on EMTs’ lives shows a much different picture...
-
In some episodes of Medic Mindset, Ginger Locke interviews paramedics who she affectionately calls the “medic-next-door.” Their stories are ...
-
Background: Physical activity has been linked to reduced risk of various cardiometabolic disease, cancer, and premature mortality. We invest...
-
BACKGROUND: This study extends what is known about long-term health-related quality of life (HrQoL) and other psychosocial outcomes (i.e., d...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου